Pages that link to "Q34113460"
Jump to navigation
Jump to search
The following pages link to Oncogenic KRAS signalling in pancreatic cancer (Q34113460):
Displaying 50 items.
- Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment (Q26740619) (← links)
- Perspectives in the treatment of pancreatic adenocarcinoma (Q26797248) (← links)
- The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas (Q27021883) (← links)
- Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma (Q28069864) (← links)
- Advances and Challenges on Cancer Cells Reprogramming Using Induced Pluripotent Stem Cells Technologies (Q28071879) (← links)
- Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer (Q28073765) (← links)
- Targeting the VEGF-C/VEGFR3 axis suppresses Slug-mediated cancer metastasis and stemness via inhibition of KRAS/YAP1 signaling (Q28078716) (← links)
- Pancreatic cancer, treatment options, and GI-4000 (Q28083814) (← links)
- Regulation of Cellular Identity in Cancer (Q28086849) (← links)
- Technologies for controlled, local delivery of siRNA (Q28087657) (← links)
- Identification of KCa3.1 Channel as a Novel Regulator of Oxidative Phosphorylation in a Subset of Pancreatic Carcinoma Cell Lines (Q28553394) (← links)
- Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. (Q30313606) (← links)
- Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions? (Q31012680) (← links)
- Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward (Q33624574) (← links)
- Miniaturized Real-Time PCR on a Q3 System for Rapid KRAS Genotyping (Q33649652) (← links)
- Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research. (Q33730022) (← links)
- Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis (Q33754779) (← links)
- Utilizing somatic mutation data from numerous studies for cancer research: proof of concept and applications (Q33835909) (← links)
- Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment. (Q33838679) (← links)
- Disease pathways at the Rat Genome Database Pathway Portal: genes in context-a network approach to understanding the molecular mechanisms of disease (Q34312452) (← links)
- Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo (Q34518484) (← links)
- Dual roles of NRF2 in tumor prevention and progression: possible implications in cancer treatment (Q35118710) (← links)
- Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies (Q35136815) (← links)
- ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer (Q35578938) (← links)
- Deregulation of the MiR-193b-KRAS Axis Contributes to Impaired Cell Growth in Pancreatic Cancer (Q35612378) (← links)
- Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer (Q35801876) (← links)
- Surveying the serologic proteome in a tissue-specific kras(G12D) knockin mouse model of pancreatic cancer (Q35842473) (← links)
- Integrated Genomic Analysis of Pancreatic Ductal Adenocarcinomas Reveals Genomic Rearrangement Events as Significant Drivers of Disease (Q35871175) (← links)
- Pancreatic cancer, treatment options, and GI-4000. (Q35887099) (← links)
- A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer (Q36000183) (← links)
- Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis (Q36092550) (← links)
- Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma (Q36103351) (← links)
- An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC). (Q36111466) (← links)
- A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells (Q36140634) (← links)
- Multiscale mutation clustering algorithm identifies pan-cancer mutational clusters associated with pathway-level changes in gene expression (Q36272766) (← links)
- Tissue-specific tumorigenesis: context matters (Q36296335) (← links)
- Clinical next generation sequencing to identify actionable aberrations in a phase I program (Q36299589) (← links)
- A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma (Q36437111) (← links)
- Amplification-free in situ KRAS point mutation detection at 60 copies per mL in urine in a background of 1000-fold wild type (Q36563555) (← links)
- ATP13A3 and caveolin-1 as potential biomarkers for difluoromethylornithine-based therapies in pancreatic cancers (Q37077387) (← links)
- Challenges in detecting pre-malignant pancreatic lesions during acute pancreatitis using a serum microRNA assay: a study based on KrasG12D transgenic mice (Q37225647) (← links)
- Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma (Q37254508) (← links)
- Actionable Intelligence Provided by Pancreatic Cancer Genomic Landscape: Are Targets for Curative Therapy On The Map? (Q37265792) (← links)
- An analysis of the relationship between metastases and cachexia in lung cancer patients (Q37321143) (← links)
- Genetic ablation of Smoothened in pancreatic fibroblasts increases acinar-ductal metaplasia. (Q37343012) (← links)
- Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic (Q37376094) (← links)
- A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth. (Q37536867) (← links)
- Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer. (Q37565338) (← links)
- ZFP36L2 promotes cancer cell aggressiveness and is regulated by antitumor microRNA-375 in pancreatic ductal adenocarcinoma. (Q37611692) (← links)
- Targeting RNA for processing or destruction by the eukaryotic RNA exosome and its cofactors (Q37661690) (← links)